Key Takeaways
- Sharp Q4 rebound, full-year turnaround: Revenue jumped 26% QoQ and EBITDA margin recovered to 8% from 6.3%, closing a year in which EBITDA rose 400% and PAT 453% after a severe two-year destocking cycle.
- Demand is stabilizing, not yet predictable: Some product categories saw revival, but management describes the environment as volatile with sudden demand shifts and refuses to give forward guidance.
- A long-term supply contract goes live: Plant commissioning and trials are complete for a deal signed in July 2024 with a multinational; supplies start in Q2, adding a visible revenue stream allied to core strengths.
- Phosphorus chemistry remains the moat: Decades of backward integration and a portfolio built around phosphorus chemistry keep the company advantaged through cycles, though future opportunities will be evaluated agnostically.
- What to watch next quarter: The ramp-up of the new supply contract, any further demand stabilization in agrochemicals, and progress on the biocide capacity expansion and new R&D center.
Demand & Cycle
- The destocking hangover lifted, partially: The company entered FY25 after two years of severe destocking that crushed revenue and margins in FY23-24. Demand revived in some product categories during the year, but volatility persisted with sudden pattern changes that make the outlook hard to call.
- Stabilization, not conviction: Management sees some stabilization but will not call a durable recovery, saying only that it must "wait and watch to see how things are going forward."
- Volume led the recovery: Full-year revenue growth of ~18% YoY was a combination of volume and pricing but largely driven by volume growth.
- Exports are a swing factor: Exports had gone up, came down, and are now increasing again, with a changed product and geographical mix that carries exposure to global cycles. The company is looking at opportunities in the USA and other markets, particularly in water treatment.
Shroff: "So general environment is of uncertainty and a lot of volatility. So it would be difficult to give you any forward-looking guidance. Generally, we don't want to go into giving guidance, but I can only tell you that there's a lot of uncertainty on policies, etc., globally."
New Contract & Growth Initiatives
- Supply contract ready to ship: A long-term supply contract with a multinational, signed in July 2024 and allied to the company's core strength and capabilities, has completed plant commissioning and production trials. Supplies are expected to start from Q2 of this financial year and will contribute to revenues from that quarter.
- Biocide capacity doubling: Rs. 10.3 crores invested to double capacity for an existing biocide product where demand is strong; the expansion comes online by H2 FY26. The company is also developing a portfolio of additional biocides in chemistries where it has strength, viewing biocides as a key area for growing market position.
- New R&D center incoming: A corporate R&D center, with a planned spend of roughly Rs. 15 crores, has been location-finalized and is targeted to operationalize in H1 of this financial year. It will focus on process development, new product opportunities, and application-oriented products.
- Volume and product expansion underway: The company is working on expanding volumes in its current product set and developing products complementary to the existing range, while also looking at opportunities that extend the product range where some advantage exists in manufacturing, existing assets, market position, or technology.
Competitive Position & Chemistry
- Phosphorus is the core: Phosphorus chemistry is a core strength; the entire portfolio is built around it, keeping the company at an advantageous position in managing cycles. Excel has been manufacturing phosphorus-based products for four to five decades and was at one point backward integrated into manufacturing its own phosphorus.
- Limited China exposure: The company has very limited, if at all, exposure to China in its supply chain and does not buy phosphorus from China. Management does not believe China is a key determinant of phosphorus pricing today.
- Agrochemical intermediates are globally competitive: Management states that its agrochemical intermediates are comparable to global capacities.
- Future opportunities will be agnostic: While phosphorus chemistry is the historic strength, the company also has strength in other chemistries and technologies. Going forward, opportunities will be evaluated agnostically, not necessarily only based on phosphorus.
Shroff: "We don't buy phosphorus from China, so I can at least clearly tell you that. And I don't know about what happens in the market, but I don't think China is a key determinant of the phosphorus pricing today."
Operations & Capacity
- Utilization has headroom: Current capacity utilization is 70-75%, consistent with ongoing optimization and operational strategies. The typical maximum effective utilization for chemical companies is 85-90% due to the need for operational flexibility and periodic maintenance. There is high fungibility within assets, but dedicated product lines are maintained for reliability.
- CAPEX plan set at Rs. 200-300 crores over three years: The company targets roughly Rs. 200-300 crores of capital expenditure over the next three years, covering maintenance, modernization, and growth initiatives. About Rs. 40-50 crores per year is earmarked for maintenance and modernization; any additional CAPEX will focus on growth-oriented opportunities.
- Asset turnover target: For future growth CAPEX, the company is looking at 1.25 to 1.5 times as asset turnover, subject to the products picked and specific opportunities.
- Gross block to revenue walk: From 2019 to 2024, Rs. 346 crores of CAPEX was invested across maintenance, process optimization, cost management, and selected business projects, plus the Vizag acquisition added ~Rs. 100 crores. Revenue growth from ~Rs. 800 crores to ~Rs. 1,000 crores reflects volume growth despite price variability; some older assets were replaced with newer ones, and environmental spending has increased due to regulatory requirements and proactive steps.
- Renewable power push: The company entered a long-term agreement to purchase solar power in the last financial year; 48% of total electricity requirements now come from renewable sources.
Margins & Strategy
- Margin target set at 13-15% EBITDA: Management aims to stay in the 13-15% EBITDA margin range, with the focus on getting into higher-margin specialty chemicals, improving capacity utilization, supply chain efficiencies, and process improvement.
- Q4 margin bounce was demand-led: EBITDA margins improved to 8% in Q4 from 6.3% in Q3 FY25, largely due to improved demand in certain key products.
- Pricing strategy tied to supplier preference: Pricing is an important part of strategy and goes hand-in-hand with making sure the company continues to be a preferred supplier. The company tracks market share and works closely with customers.
- Concentration is acknowledged: The top 10 products account for roughly 90% of revenues. Management is aware of concentration risk and has taken steps to reduce it, though it declines to share specific product-level data for competitive sensitivity.
Shroff: "Pricing is an important part of our strategy, and it goes very well hand-in-hand with making sure that we continue to be preferred suppliers."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| New supply contract revenue start | Supplies begin, contributing to revenues | Q2 FY26 |
| R&D center operational | New corporate R&D center live | H1 FY26 |
| Biocide capacity expansion complete | Capacity doubled for existing biocide product | H2 FY26 |
| CAPEX spend | Rs. 200-300 crores total, ~Rs. 40-50 crores/year maintenance | Over next 3 years |
| EBITDA margin range | Stay in 13%-15% range | Ongoing target |
| Growth CAPEX asset turnover | 1.25x to 1.5x on future growth CAPEX | Subject to product/opportunity selection |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹248 cr, +26% QoQ |
| EBITDA | ₹20 cr, +61% QoQ |
| EBITDA margin | 8.0%, vs 6.3% in Q3 FY25 |
| Profit after tax | ₹11 cr, vs ₹6 cr in Q3 FY25 |
| FY25 revenue | ₹978 cr, +18% YoY |
| FY25 EBITDA | ₹121 cr, +400% YoY |
| FY25 EBITDA margin | 12.3%, vs 2.9% in FY24 |
| FY25 profit after tax | ₹84 cr, +453% YoY |
| Agrochemical intermediates share | 50%–60% of portfolio |
| Specialty chemicals share | 20%–30% of portfolio |
| Polymer additives share | 5%–8% of portfolio |
| Pharma intermediates and API share | 4%–8% of portfolio |
| Export share | 18% of overall revenue |
| Capacity utilization | 70%–75% |
| Target EBITDA margin range | 13%–15% |
| Planned capex over next 3 years | ₹200–300 cr |
| FY19–FY24 cumulative capex | ~₹346 cr |
| Annual maintenance and modernization capex | ₹40–50 cr |
| R&D center investment | ~₹15 cr |
| Biocide capacity expansion investment | ₹10.3 cr, to double capacity |
| Renewable electricity share | 48% of total requirements |
| Environment business share | ~1% of total revenues |
| Phosphorus-based chemistry share | ~80% of revenues |
| Top 10 products share | ~90% of revenues |
| Current asset turnover | ~2.5x |
| Target asset turnover for growth capex | 1.25–1.5x |